首頁 > 市場調查報告書 > 製藥

全球罕見腎臟疾病治療市場研究報告——2023-2030 年行業分析、規模、份額、增長、趨勢和預測

市場調查報告書

商品編碼

1267298

全球罕見腎臟疾病治療市場研究報告——2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Rare Kidney Diseases Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年04月01日 | 出版商:

Value Market Research | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球對罕見腎髒病治療市場的需求將從 2022 年的 70.4 億美元增加到 2030 年的近 151.3 億美元，複合年增長率為 10.04% 在 2023-2030 年的研究期間預計將達到

罕見的腎臟疾病是一組影響腎臟並可能導致腎衰竭的疾病。它因基因突變、感染性疾病、自身免疫性疾病等多種因素而發展，可出現腎功能衰竭、蛋白尿、高血壓等多種症狀。罕見的腎臟疾病通常採用藥物治療、生活方式改變、透析和移植相結合的方法進行治療。由於流行率低和知識匱乏，這些疾病往往很困難。

市場動態：

對更有效的罕見腎臟疾病治療和治愈方法的需求不斷增長，推動了該行業的興起。此外，人們對這些疾病的認識和了解的提高有望推動罕見腎病治療市場的擴大。此外，關於罕見腎臟疾病的研究和知識的增加也促進了市場的增長。此外，對更有效的治療和治療罕見腎臟疾病的需求不斷增加，也促進了市場的增長。然而，高昂的處理成本可能會阻礙市場增長。

這份研究報告解釋了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。此外，這些工具還對全球罕見腎病治療市場的每個細分市場進行了全面評估。罕見腎臟疾病治療行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

本部分按國家/地區提供詳細的細分數據，以幫助您確定每種產品/服務的目標受眾和未來商機。

按藥物類別

□替代療法
單克隆抗體
其他

按展示

法布裡病
非典型溶血性尿毒症綜合徵
狼瘡性腎炎
腎病性胱氨酸增多症
其他

按分銷渠道

醫院藥房
零售藥房
在線銷售

按地區分析：

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲、中東和非洲對罕見腎臟疾病治療市場當前和未來的需求。此外，我們還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。罕見腎病治療市場的主要參與者是 Calliditas Therapeutics AB、GSK plc、Aurinia Pharmaceuticals Inc.、Amicus Therapeutics Inc.、Shire（武田製藥）、賽諾菲、Advicenne、Alexion Pharmaceuticals Inc、Horizo□□n Therapeutics plc、Otsuka Pharmaceutical Co. Ltd ., Reata Pharmaceuticals Inc. 本節概述了競爭格局，包括各種戰略發展，如主要併購、未來能力、合作夥伴關係、財務概覽、聯合研究、新產品開發和新產品發布。

內容

第一章前言

報告內容
- 目的
- 目標受眾
- USP（獨特的銷售建議）及其提供的內容
調查範圍
調查方法
- 市場調研流程
- 市場研究方法

第 2 章執行摘要

市場亮點
全球市場概況

第 3 章罕見腎髒病治療 - 行業分析

簡介 - 市場動態
市場驅動力
市場製約因素
機會
行業趨勢
波特的五力分析
市場吸引力分析
- 按藥物類別進行的市場吸引力分析
- 按適應症分類的市場吸引力分析
- 按分銷渠道進行的市場吸引力分析
- 市場吸引力分析：按地區

第四章價值鏈分析

價值鏈分析
原材料分析
- 原材料清單
- 原材料製造商名單
- 主要原材料價格走勢
潛在買家名單
營銷渠道
- 直接營銷
- 間接營銷
- 市場發展趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章罕見腎髒病治療的全球市場分析：按藥物分類

按藥物類別匯總
過去和未來的數據
按藥物類別分析
□替代療法
單克隆抗體
其他

第 7 章罕見腎髒病療法的全球市場分析：按適應症分類

功效概述
過去和未來的數據
適應症分析
法布裡病
非典型溶血性尿毒症綜合徵
狼瘡性腎炎
腎病性胱氨酸增多症
其他

第 8 章稀有腎臟藥物的全球市場銷售分析：按分銷渠道

按分銷渠道概述
過去和未來的數據
按分銷渠道分析
醫院藥房
零售藥房
在線銷售

第 9 章罕見腎髒病療法的全球市場銷售分析：按地區

按地區進行的銷售前景分析
介紹銷售分析
北美銷售分析
- 概覽、歷史和預測銷售分析
- 北美各部門的銷售分析
- 北美銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測銷售分析
- 按細分市場進行的歐洲銷售分析
- 按國家/地區劃分的歐洲銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 意大利銷售分析
- 俄羅斯銷售分析
- 其他歐洲銷售分析
亞太地區銷售分析
- 概覽、歷史和預測銷售分析
- 亞太地區各部門的銷售分析
- 亞太國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本的銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 其他亞太地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測銷售分析
- 拉丁美洲各部門的銷售分析
- 拉丁美洲國家/地區的銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利的銷售分析
- 其他拉丁美洲銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測銷售分析
- 中東和非洲各細分市場的銷售額分析
- 中東和非洲國家/地區的銷售分析
- 沙特阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 其他中東和非洲銷售分析

第 10 章：罕見腎病治療公司的競爭狀況

稀有腎臟治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他擴展

第11章公司簡介

前 10 名公司的市場份額分析
市場集中度
Calliditas Therapeutics AB
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
葛蘭素史克公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Aurinia 製藥公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Amicus Therapeutics Inc.
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Shire（武田製藥有限公司）
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
賽諾菲
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
建議
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Alexion 製藥公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Horizo□□n Therapeutics plc
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
大塚製藥有限公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Reata 製藥公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢

注意：在公司簡介、財務細節、近期發展等方面，基於可用信息，私人控股公司可能不包括在內。

簡介目錄圖表

Product Code: VMR11219954

The global demand for Rare Kidney Diseases Treatment Market is presumed to reach the market size of nearly USD 15.13 BN by 2030 from USD 7.04 BN in 2022 with a CAGR of 10.04% under the study period 2023 - 2030.

Rare kidney diseases are a group of conditions that affect the kidneys and can lead to kidney failure. They can be caused by various factors, including genetic mutations, infections, and autoimmune disorders, and may have a wide range of symptoms, including kidney damage, proteinuria, and high blood pressure. Rare kidney disease treatment often involves a combination of medications, lifestyle modifications, and dialysis or transplantation. It is often challenging due to the low prevalence and lack of knowledge about these conditions.

Market Dynamics:

The increasing demand for more effective treatments and therapies for rare kidney diseases has contributed to the rise of this field. Moreover, the growing awareness and understanding of these conditions may drive the rare kidney disease treatment market to increase. Furthermore, increased research and knowledge about rare kidney diseases have led to market growth. In addition, the increasing demand for more effective treatments and therapies for rare kidney diseases has contributed to the market's rise. However, the high cost of treatment may hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rare kidney diseases treatment. The growth and trends of rare kidney diseases treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the rare kidney diseases treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Enzyme Replacement Therapy
Monoclonal Antibodies
Others

By Indication

Fabry Disease
Atypical Hemolytic Uremic Syndrome
Lupus Nephritis
Nephropathic Cystinosis
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Sales

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Rare Kidney Diseases Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the rare kidney diseases treatment market include Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals Inc., Amicus Therapeutics Inc., Shire (Takeda Pharmaceutical Company Limited), Sanofi, Advicenne, Alexion Pharmaceuticals Inc., Horizon Therapeutics plc, Otsuka Pharmaceutical Co. Ltd., Reata Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . RARE KIDNEY DISEASES TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Enzyme Replacement Therapy Historic and Forecast Sales by Regions
6.5 Monoclonal Antibodies Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Fabry Disease Historic and Forecast Sales by Regions
7.5 Atypical Hemolytic Uremic Syndrome Historic and Forecast Sales by Regions
7.6 Lupus Nephritis Historic and Forecast Sales by Regions
7.7 Nephropathic Cystinosis Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
8.5 Retail Pharmacies Historic and Forecast Sales by Regions
8.6 Online Sales Historic and Forecast Sales by Regions

9 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE RARE KIDNEY DISEASES TREATMENT COMPANIES

10.1. Rare Kidney Diseases Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF RARE KIDNEY DISEASES TREATMENT INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Calliditas Therapeutics AB
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. GSK plc
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Aurinia Pharmaceuticals Inc.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Amicus Therapeutics Inc.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Shire (Takeda Pharmaceutical Company Limited)
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Sanofi
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Advicenne
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Alexion Pharmaceuticals Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Horizon Therapeutics plc
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Otsuka Pharmaceutical Co. Ltd.
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Reata Pharmaceuticals Inc.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表